Edinburgh, UK – 1st of June 2023: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces it has expanded its Senior Management team with the appointments of VP of Sales, Roberto Marcucci, Chief Technology Officer, Dr David Bramwell, Chief Financial Officer, Phil Pattison and Chairman, Albert Nicholl.
Roberto Marcucci, Vice President of sales EU
Roberto is an experienced Senior Sales Manager with nearly 20 years of demonstrated successes in selling SaaS and medical devices. He has a passion for innovative Health-Tech solutions with a special interest in Neurosurgery/Neurology, having previously built a renowned distribution network from scratch in such spaces. Roberto’s proficient sales attributes ideally positions him to execute on the Company’s sales strategy for the innovative NeuroMotorTM Pen (‘NMP’).
Dr David Bramwell, PhD, Chief Technology Officer
David is a technical software development specialist and a founder of Biosignatures Ltd, which focused on the discovery and validation of novel AI marker panels for the diagnosis of disease. Prior to this he was Technical Director at Nonlinear Dynamics Ltd, where he led the development of the flagship Progenesis product line. David is responsible for the technology delivery of the NeuroMotorTM Pen to realise its potential in positively impacting millions of lives. His focus is on driving continual improvement across all aspects of product delivery by building on the Quality Management Systems.
Phil Pattison, Chief Financial Officer
Phil is an experienced finance and commercial professional, who has held various Executive and Non-Executive positions for numerous blue-chip companies including; General Electric, Rolls-Royce, Marks and Spencer, Worldmark International (Private Equity backed) and Royal IHC. In 2005 he and other fellow directors set up a specialist healthcare company which floated on AIM. Phil is a Fellow of the Chartered Institute of Management Accountants, he holds an MBA from Newcastle University Business School and is a GE Six Sigma Black Belt..
Albert Nicholl, Chairman
An experienced Life Science and MedTech veteran, Albert has extensive commercial and management experience in healthcare and medical devices having worked at a senior level in companies such as Stryker and Orthofix. In recent years he has worked in a variety of Non-Executive Director and Chair roles, supporting growing companies in the sector to raise investment, build great teams and commercialise successfully.
Dr Rutger Zietsma, CEO of Manus, commented: “We are delighted to have expanded our Senior Management team with the above appointments, broadening the wealth of experience and knowledge to help implement our commercialization strategy as we enter our next phase of growth for NMP. It is the ideal time to grow the team with an exciting year ahead and demonstrates the support and belief in our non-invasive, CE-marked product which will revolutionise neurological healthcare as we know it, attracting such a high-calibre, skilled group of professionals.”
Enquires
| Manus Neurodynamica Ltd Dr Rutger Zietsma, Chief Executive Officer | +44 131 563 5465 r.c.zietsma@manusneuro.com |
| Walbrook PR (PR advisors to Manus) Lianne Applegarth / Phil Marriage | +44 20 7933 8780 +44 7584 391 303 / +44 78 67 984 0 82 manusneuro@walbrookpr.com |
Notes to Editors
About Manus Neurodynamica – www.manusneuro.com
Dr Rutger Zietsma founded Manus. The Company’s main activity is designing, patenting and marketing innovative technologies used in medical devices and personal care products which have the capability to improve people’s health and wellbeing. The Company implements quality procedures to medical standards.
The principal product is the NeuroMotor Pen™ (NMP) designed for use in the diagnosis and monitoring of neuromotor impairments. As a first indication, the pen has been configured for use in Parkinson’s disease and tremor differentiation and uses limb and hand motion to diagnose patients quickly and non-invasively. It has applications across not just diagnosis but also screening, monitoring, rehabilitation and drug development for a number of different neurological disorders.
About NeuroMotor PenTM
is a unique, patented and CE-marked system that combines sensor technologies built into a digital pen with software and an analytical engine with Decision Support System, using AI. The interface enables users to record non-invasively and analyse parameters of minute limb and hand motion. This enables quantification of fine motor skill. These parameters are used as ‘digital biomarkers’ to provide objective information about movement abnormalities. NMP can be used to support differential diagnosis and monitoring of movement disorders and other neuromotor impairments. It has the potential to be a quick, inexpensive, non-invasive, and objective aid to diagnosis that can provide a low-cost alternative to brain scans. There are additional applications in prevention screening, monitoring, rehabilitation and drug development for a number of different neurological disorders.
Breakthrough Designation has been granted by the FDA for the proposed indication of using the NeuroMotor PenTM to support health care providers (HCPs) in differentiating between Parkinsonian and non-Parkinsonian tremors in adult patients who are suspected to have Parkinson’s Disease (PD) but have not been diagnosed by other means.